Antithrombins and the importance of good control

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 3, 1999, Pages 444-451

  Tideman, P A ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Acute coronary syndrome; Direct anti thrombin; Heparin; Hirudin; Hirulog; Low molecular weight heparin; Structure function relationship; Thrombin

Indexed keywords

ANTITHROMBIN; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN;

ATHEROSCLEROTIC PLAQUE; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; THROMBOSIS PREVENTION;

EID: 0033025971     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00741.x     Document Type: Conference Paper

References (36)

1. 1. Furie B, Furie BC. Molecular and cellular biology and blood coagulation. N Engl J Med 1992; 326: 800-6.
2. 2. Rihal CS, Flather J, Hirsh J, Yusuf S. Advances in antithrombotic drug therapy for coronary artery disease. Eur Heart J 1995; 16: (Suppl. D): 10-21.
3. 3. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
4. 4. Kelly AB, Maraganore JM, Bourbon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992; 89: 6040-4.
5. 5. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
6. 6. Weitz J. New anticoagulant strategies - current status and future potential. Drugs 1994; 48: 485-97.
7. 7. Hirsh J, Fuster V. Guide to anticoagulant activity: Part I. Circulation 1994; 89: 1449-68.
8. 8. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
9. 9. Theroux P, Ouimet H, McCans J, Latour J, Joly P, Levy G. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
10. 10. The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
11. 11. Hsia J, Hamilton WP, Kleimann N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction: Heparin-Aspirin Reperfusion Trial Investigators. N Engl J Med 1990; 323: 1433-7.
12. 12. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary artery patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
13. 13. De Bono DP, Simoons ML, Tijssen J et al., and the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised, double-blind European cooperative study group trial. Br Heart J 1992; 67: 122-8.
14. 14. Granger CB, Hirsh J, Califf RM et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation 1996; 93: 870-8.
15. 15. Cohen M, Demers C, Gurfinkel EP et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
16. 16. Klein W, Buchwald A, Hillis Se et al. Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary disease. Circulation 1997; 96: 61-8.
17. 17. Johnson PH, Sze P, Winant R et al. Biochemistry and genetic engineering of hirudin. Semin Thromb Hemost 1989; 15: 302-15.
18. 18. Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 89: 377-88.
19. 19. Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Drug Res 1988; 38: 704-10.
20. 20. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterisation of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101.
21. 21. Fox I, Dawson A, Loynds P et al. Anticoagulant activity of Hirulog [tm], a direct thrombin inhibitor in humans. Thromb Hemost 1993; 69: 157-63.
22. 22. Lidon R, Theroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, Hirulog in unstable angina - anti-coagulant, antothrombotic and clinical effects. Circulation 1993; 88: 1495-501.
23. 23. Topol EJ, Fuster V, Harrington RA et al. Recombinant hirudin for unstable angina pectoris: a multicentre, randomized angiographic trial. Circulation 1994; 89: 1557-66.
24. 24. White HD, Aylward PE, Frey MJ et al. Randomized, double-blind comparison Hirulog verses heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155-61.
25. 25. Theroux P, Perez-Villa F, Waters D et al. Randomized double-blind comparison of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct related artery in acute myocardial infarction. Circulation 1995; 91: 2132-9.
26. 26. Lidon R, Theroux P, Lesperance J et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994; 89: 1567-72.
27. 27. Cannon C, McCabe C, Henry T et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
28. 28. Toplo EJ, Bonan R, Jewitt D et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 1993; 87: 1622-9.
29. 29. Bittl JA, Strony J, Brinker JA et al. Treatment with Bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable angina or post-infarction angina. N Engl J Med 1995; 333: 764-9.
30. 30. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
31. 31. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
32. 32. Neuhaus K-L, v. Essen R, Tebbe U et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT) III study. Circulation 1994; 90: 1638-42.
33. 33. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
34. 34. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.
35. 35. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
36. 36. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration and drug. Circulation 1997; 96: 2118-20.